Patients with diabetes who utilize GLP-1 RAs for 6 months or longer are twice as likely to develop neovascular age-related macular degeneration.

provider time required to initiate a GLP-1RA, which requires patient education regarding prevention and management of gastrointestinal side effects, injection technique, and dose titration. While some ...

Figure 1. Cardiovascular risk reduction in adults with type 2 diabetes: central illustration. GLP-1 indicates glucagon-like peptide 1; PCSK-9, proprotein convertase subtilisin/kexin type 9 serine ...

Novo Nordisk and Eli Lilly are currently the major players in the GLP-1RA space, but opportunity remains for new entrants. 7.4 Where Are GLP-1RAs Expected to Position in the Future Chronic Kidney ...

Moreover, cessation of GLP-1RA therapy can result in a rebound in body weight in favour of fat mass and at the expense of LBM, resulting in a less favourable muscle to fat ratio 3. S-pindolol ...

Moreover, cessation of GLP-1RA therapy can result in a rebound in body weight in favour of fat mass and at the expense of LBM, resulting in a less favourable muscle to fat ratio 3. S-pindolol benzoate ...

Despite early success, however, Novo Nordisk has fallen behind in the GLP-1RA race, overtaken by Eli Lilly and its GLP-1RA asset tirzepatide, respectively sold under the brand names Zepbound and ...

While bring in this role, Jørgensen had helped steer the company to the forefront of the biggest drugmakers in the world. Image credit: MADS CLAUS RASMUSSEN/AFP via Getty Images. Novo Nordisk is ...